Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Hartmann

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study GroupAnja Lorch, Christian Kollmannsberger, Joerg Thomas Hartmann, et al.
Genes, Chromosomes & Cancer|September 27, 2012
High frequency of MYC gene amplification is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01Christoph Käcker, Alexander Marx, Katharina Mössinger, et al.
Cancer Chemotherapy and Pharmacology|September 15, 2010
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumorsRobert S Benjamin, Patrick Schöffski, Jörg Thomas Hartmann, et al.
The American Journal of Pathology|December 17, 2009
MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedemaJohanna Manner, Bernhard Radlwimmer, Peter Hohenberger, et al.
The Lancet. Oncology|September 23, 2011
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesPatrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische OnkologieSalah-Eddin Al-Batran, Joerg Thomas Hartmann, Stephan Probst, et al.
Journal of Environmental Management|February 26, 2022
Identifying barriers for nature-based solutions in flood risk management: An interdisciplinary overview using expert community approachPavel Raška, Nejc Bezak, Carla S S Ferreira, et al.
Cancer Cell|November 16, 2004
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2Jonathan Oliner, Hosung Min, Juan Leal, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study GroupAnja Lorch, Christian Kollmannsberger, Joerg Thomas Hartmann, et al.
Genes, Chromosomes & Cancer|September 27, 2012
High frequency of MYC gene amplification is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01Christoph Käcker, Alexander Marx, Katharina Mössinger, et al.
Cancer Chemotherapy and Pharmacology|September 15, 2010
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumorsRobert S Benjamin, Patrick Schöffski, Jörg Thomas Hartmann, et al.
The American Journal of Pathology|December 17, 2009
MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedemaJohanna Manner, Bernhard Radlwimmer, Peter Hohenberger, et al.
The Lancet. Oncology|September 23, 2011
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesPatrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische OnkologieSalah-Eddin Al-Batran, Joerg Thomas Hartmann, Stephan Probst, et al.
Journal of Environmental Management|February 26, 2022
Identifying barriers for nature-based solutions in flood risk management: An interdisciplinary overview using expert community approachPavel Raška, Nejc Bezak, Carla S S Ferreira, et al.
Cancer Cell|November 16, 2004
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2Jonathan Oliner, Hosung Min, Juan Leal, et al.
Pageof 14